Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics develops small molecule drugs, led by an investigational kinase inhibitor for chronic myeloid leukemia. It last closed at $46.85 on Nov 17, down 1.62% on the day. The average 12-month price target from 3 analysts is $72.67 (+55.1% from the last close), with a high of $75.00 and a low of $70.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $897K, the largest $897K.
Key Stats
Last 12 monthsNot reported for this period.
From ELVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ELVN in the past 90 days. The average target is $72.67, with a high of $75.00 and a low of $70.00, compared with the last close of $46.85.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Target raised | Buy | $64 → $73 |
| Oct 2 | Morgan Stanley | Initiated | Buy | $70 |
| Oct 1 | JP Morgan | Initiated | Buy | $75 |
| Aug 18 | Barclays | Initiated | Buy | $78 |
| Aug 18 | Mizuho | Target raised | Buy | $62 → $73 |
Technical Analysis
The stock is 2% above its 20 day and 2% above its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 51). The nearest support is the 20 day average at $46.05, and the nearest resistance the Pivot at $46.88.
| RSI (14) | 51.10 | Middle of its range | Neutral |
| MACD | 1.09 | Above its signal line | Bullish |
| Stochastic | 52.4 | Middle of its range | Neutral |
| ADX (14) | 24.6 | Weak trend | |
| Williams %R | -59.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 24.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.5% | Change over 10 sessions | Bullish |
| ATR (14) | $2.17 | Typical daily range, 4.6% of price |
| RSI (14) | 50.77 | Middle of its range | Neutral |
| MACD | 0.77 | Below its signal line | Bearish |
| Stochastic | 45.3 | Middle of its range | Neutral |
| ADX (14) | 29.5 | Trending up | |
| Williams %R | -60.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -41.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −13.8% | Change over 10 sessions | Bearish |
| ATR (14) | $5.16 | Typical daily range, 11.0% of price |
What happened before
See how ELVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ELVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ELVN in the last 90 days.
Dark Pool
30DELVN Institutional Ownership
Full report →- ▲135 buying vs 85 selling
- ▲Held by funds +2.9 pts
- ▲Funds holding +5
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 218 | 213 | +2.3% |
| In funds' top 10 | 10 | 13 | −23.1% |
| Held by funds | 112.3% | 109.3% | +2.9 pts |
| New / increased | 38 / 97 | 61 / 86 | −8.2% |
| Reduced / sold out | 53 / 32 | 48 / 20 | +25.0% |
| Put/call ratio | 0.01 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELVN is in one of them and how their past ELVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ELVN in an article yet. Here's the latest on the wider market.
About Enliven Therapeutics
Enliven Therapeutics is a biopharmaceutical company based in Burlingame, California, that develops small molecule drugs. Its lead candidate, ELVN-001, is a kinase inhibitor being studied for chronic myeloid leukemia, a blood cancer, in patients whose disease has become resistant or intolerant to existing treatments. The company also runs research programs on other targeted therapies aimed at unmet medical needs.
- Headquarters
- Burlingame, CA


